Posted by Michael Wonder on 24 Nov 2020
'Disappointing' delay for new type 2 diabetes drugs that stop kidney failure and save lives
24 November 2020 - Kim Dennis is one of few New Zealanders who knows what it’s like to manage their type 2 diabetes with modern medication.
The 67 year-old from South Auckland had one word for PHARMAC’s decision to delay funding of life-changing type 2 diabetes medicines dulaglutide and empagliflozin: “Disappointing.”
